Marillion to initiate Phase I trial of anticancer drug
The trial will evaluate the safety and pharmacology of vitamin D5 analog, MN-201 in patients with advanced tumors in various cancers. The protocol for the clinical trial is
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.
This patent includes composition of matter, pharmaceutical composition, method of treatment, and synthetic method claims directed to heat shock protein 90 (Hsp90) inhibitor and other hydroquinone-containing ansamycin analogues.
Targacept plans to advance TC-5214, one of two enantiomers of mecamylamine hydrochloride, into clinical development as an augmentation therapy for patients who are inadequate responders to first-line antidepressant